Peripheral catecholamine alterations in adolescents with polycystic ovary syndrome.
OBJECTIVE
Polycystic ovary syndrome (PCO) is one of the most common endocrine disorders affecting women. Several lines of evidence have suggested the involvement of the sympathetic nervous system (SNS) in this condition. The present work was designed to assess neurochemically SNS activity in patients during the early stages of PCO.


METHODS
Fourteen patients with PCO (aged 14 to 21 years) were studied on a random day and 9 normal regularly cycling adolescents (aged 14 to 20 years) were studied during the early follicular phase (days 2 to 5).


METHODS
Hormonal profile was determined in basal conditions. LH and FSH were also measured after i.v. administration of 100 micrograms GnRH. Plasma concentrations of dihydroxyphenylalanine (Dopa), noradrenaline (NA), adrenaline (A), total dopamine (DA) and dihydroxyphenylglycol (DHPG) were determined in basal conditions and in response to GnRH by HPLC with electrochemical detection or a radioenzymatic method. Basal urinary Dopa, catecholamines and catechol metabolites (DHPG, vanillylmandelic acid (VMA), 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), metanephrine (MN) and normetanephrine (NMN)) were determined by HPLC with electrochemical detection.


RESULTS
Basal plasma LH, testosterone, androstenedione, oestrone and LH/FSH ratio were higher (P < 0.01) and serum sex hormone-binding globulin (SHBG) were lower (P < 0.01) in PCO patients than in control subjects. Basal and GnRH-stimulated plasma free Dopa, A, NA and total DA were similar in patients and controls. Plasma DHPG was lower (P < 0.01) in PCO patients (4.20 +/- 0.30 nmol/l) than in controls (8.0 +/- 1.0 nmol/l) throughout the study. Urinary A, NA, DA, Dopa, MN, MHPG, HVA, and VMA were similar in patients and controls. Urinary DHPG was lower (P < 0.01) in PCO patients (0.50 +/- 0.02 mumol/d) than in controls (0.73 +/- 0.09 mumol/d). On the other hand PCO patients had a higher urinary excretion of NMN than controls (PCO: 1.20 +/- 0.10; C: 0.78 +/- 0.10 mumol/d, P < 0.05).


CONCLUSIONS
Our results show the same endocrinological features in adolescent PCO patients as those reported in adults. The results also demonstrate a peripheral catecholaminergic alteration which suggests an alteration in noradrenaline deamination and/or uptake in adolescent patients. This study however does not permit us to conclude that PCO is primarily caused by this sympathetic alteration.
Garcia-Rudaz
C
C
Centro de Investigaciones Endocrinologicas (CONICET), Hospital de Niños R. Gutierrez, Buenos Aires, Argentina.
Armando
I
I
Levin
G
G
Escobar
M E
ME
Barontini
M
M
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D000728:Androgens / Q000097:blood; D016022:Case-Control Studies; D002395:Catecholamines / Q000097:blood* / Q000652:urine; D004295:Dihydroxyphenylalanine / Q000097:blood; D004298:Dopamine / Q000097:blood; D004967:Estrogens / Q000097:blood; D005260:Female; D007987:Gonadotropin-Releasing Hormone; D006065:Gonadotropins, Pituitary / Q000097:blood; D006801:Humans; D008597:Menstrual Cycle; D011085:Polycystic Ovary Syndrome / Q000097:blood* / Q000503:physiopathology / Q000652:urine; D012738:Sex Hormone-Binding Globulin / Q000032:analysis; D013564:Sympathetic Nervous System / Q000503:physiopathology*
D000728:Androgens; D002395:Catecholamines; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D012738:Sex Hormone-Binding Globulin; D007987:Gonadotropin-Releasing Hormone; D004295:Dihydroxyphenylalanine; D004298:Dopamine